上海医药(601607.SH)：上半年净利润44.59亿元，同比增长51.56%

Core Insights - Shanghai Pharmaceuticals (601607.SH) reported a revenue of 141.593 billion yuan for the first half of 2025, reflecting a year-on-year growth of 1.56% [1] - The net profit attributable to shareholders reached 4.459 billion yuan, marking a significant year-on-year increase of 51.56% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 2.01 billion yuan, which represents a year-on-year decline of 22.38% [1] - The basic earnings per share stood at 1.20 yuan [1]